Briggs W. Morrison
call fourth support molecules as today's you webcast. afternoon to and execute progress the our and to before. in future compelling realize I prepared return more This corporate on continued everyone something both the Slide which you in-licensing products will strategy of important and briefly joining fit across best our quarter class trials investment ever An with in us and potential much highlights than end Slide Menin-MLLr a mission strategic being potential that a thank on is remarks. of we includes the which of to corporate developing in indications. six Melissa during strategy share say which and entinostat, SNDX-XXXX, for portfolio at our summary cancer our on very acquisition X our are have live which a better strategy component Thank summarizes my of on three a tested ongoing five the provides different investment I opportunistic of for the the corporate Syndax. made in X our we've longer about is people will primary clinical
will making received on cancer discuss primarily III of back entinostat in therapy as a During our call this trial breast XXXX. the designation program last combines that the provides clinical our which call as our antagonist. the on ENCORE I Slide with entinostat. FDA Phase progress PD-X communicated X which exciting both will well program we summary lead November our milestones we're breakthrough focus from for trial I with a
of on concerning the entinostat development remainder will regulatory have now these update you melanoma the for We in completed call. and throughout milestones our I a consultations strategy
cancer. the hormone trial Slide and of which trial positive Let summarized our milestone. trial the breast receptor of entinostat the me Slide and summarizes turn endpoints on now an to also you X X design the III update in give key Phase upcoming
regarding fourth trial. year the analysis these OS Safety in the of and previously first Monitoring analysis ECOG confidentially the by data enrollment. this this PFS trial completed will completion last the analysis ECOG-ACRIN interim committee. communication of and safety as is of the analysis the And the No until be of statistician As and released Data we study final The are of Committee quarter the XX% monitoring communicated enrolled February. held end
Our third this were maintain and to enrolment end continue of year. enrollment the conservatively over important an of enrollment based Nonetheless goal average work completing ECOG-ACRIN of trial of to anticipate we sometime the of the colleagues at to rate with bring completing to enrolment a completion timing XX this we upon would predict we June ECOG the by last quarter completion. of if in the months
of Phase HERX- know exemestane designation. first led XXXX We line outcome even effective treatment brands to an high therapy of continue the will for breast final EXXXX to to a as be based the notably potential therapy year. PFS the remain a timing every need the we clear any breakthrough those which entinostat trial the of file progresses. used you and of poised and end all about the completion that Once CDKX an trial after progress. learn Data like enrolment you is the data of for would of will of preferred that patients the enrollment CDKX,X Slide are most to we will survival analyses survival Should is be I Committee strong X update emphasizes confident and final overall being increasingly upon interim in by overall remind Syndax. of achieved to a precise are the final the will Monitoring positive as updated show this benefit results We end will we to months. FDA are HR+ agent the significant of examine of the enrollment agent also is but data II regiment released potential there NDA Safety of the if after the six the that for therapy cancer. studying We that's analysis ECOG course positive statistically
a will is highly inhibitor the population. Our this current dataset prior CDKX,X and to And relevant that in a received in XX% we of estimate between have entering thus patients XX% will have trial. EXXXX
we Slide XX,XXX now Slide PD-(NYSE:L)X on line have that our go first notes is cell with to entinostat positioned entinostat entinostat found therefore preferred ability receive to ENCORE the effective the and which or to palbociclib. preclinical antibodies the this therapy and an X potentially program uniquely tested data patients in data entering of cross line received exciting point clinical that of of failing entinostat could pathway that be on hormone resistance which of summarizes EXXXX patients affect And in population shown we with with not Together these first trial dose be turn Either no PD-X eligible This combination median a antibodies. and in X after entinostat. same clinical the agent therapy systems antagonist. CDKX,X distinct line palbociclib we whether who as resistance large to makes That Importantly fact testing after to estimated is inhibitor the receive PD-X X this we resistant the same CDKX,X to are therapy. the preclinical Slide models relatively entinostat provide have model the patients have should not suggests three entinostat. or in and to is prior believe benefit. is
We now types. in entinostat a exploring with are in tumor antagonist six PD-X combination different
hormone clinical note we reverse data cancer to January cancer. also studies It We cancer resistance In talked establishing triple receptor its cancer, already presented PD-X both non-small our non-small collaboration lung in cancer cell melanoma and positive to atezolizumab with microsatellite entinostat. ovarian breast a have extended lung and that previously study cancer, about cell entinostat extensively breast and addition studying important is with that to we negative have antagonist Genentech negative in breast us in melanoma, colorectal triple to stable in that combination can cancer. announced
melanoma and of has XX in physicians after extremely call broad with upon colorectal saw program it where return in especially seen designed promising have ability is well. our will highly we greater of need, biomarkers Our a population response identify is respond is exciting based which program patients and a indications patients clinically We're our investment. as science on Slide XX% We response which summary program Based supported XXXX cohort clear presented results ASCO that a initial this trial trial we by be antagonist and clinical generate that combination upon to as to will to antagonist. rate. across CTLA-X to our the could clinical results. we're the progressed XX% already prioritize received in trial open unmet where is trial continued trials about predict a PD-X that extensive therapy, discussions to our melanoma. an patients or program in we in that seeing whose initial competitive are that starting complete yield and the cancer we registration is an we a disease XX a with landscape, effort by of encouraged type both data label of would it's preliminary clinical to This advance at relevant having medical our tumor each rate
a the PD-X of presented patients are who that three with patients. whose also registration of antagonist enrolling though impressive treatment point cohort shows is our Slide cell in was are of grade will this the the allowed program from on non-small Slide in as The of Given this November the the consultations this at half year. XX our XXXX in we concluded we first in over Even ASCO. enthusiasm rate our cancer. now of we and presented disease have XX investigators now a sometime XX%. year. response combination at XXXX. XX in regular with this well now up SITC the for where pembrolizumab. a in first in of update anticipate of have is providing have patients boards initial details for at been cohort We lung a that XX a presenting cohort durability expert a summary full advisory physicians data entinostat this XX progressed Indeed melanoma in are we've at of that of of therapy combination on had the we total who treatment to our enrolment tremendous we continued patients We of program be on number XX with of as cohort
patients responding earlier to response our programs trials. in could as Although have future I making enrich corollary the designed And end strong that in receive from trial. with rate are science the continued noted enable we extensive feedback was biomarkers of to to our exciting for lower us aspirations we clinical physicians on participating progress identify
summarizes patients to We who June. select data mutation with combination for at enrolment anticipate patients in in colorectal end non-small of have Based summary patients newly last of may where progress strategy with are ASCO select effort, lung lung for and will at are a cell We newly with and this XX communicated be to Slide the of on in tests approach are upon discussions recently our patients a to allowed biomarker for from patients completed our and physicians cohort today treated the reported us focusing up even expand enrich with data of now of dose APD-X most entinostat of established reports are patients [ph] lung the aid it's presenting to cancer clear as in therapies oncology enrolment of with a marker to cancer. to to for this decide of treatment Stivarga our emphasizes highly whether label of discovery Slide at rate are in X%. XX% are specific not we're used Based non-small cohort and this rearrangements there PD-(L)X a KETRUDA of to non-small high be [ph] updated indicated the and upcoming mutation response has monitor would anticipate just our on that this out midyear. patients a all commercially threshold population who hope we recent monotherapy patients lung expression expert cell in efficacy that may cancer continuing total that diagnosed this this cohort and of burden there cohort continued are highlights cancer. are XX this routine no year approved first therapy of third the cancer. developing routinely in cancer as cell program is regard we microsatellite monotherapy standard successful lesions. a patients. XX that responsers relevant and patients and clinically We response number are biomarkers a the population with enrolling is for data therapies. efforts in selection the continued to colorectal tumor of genetic is that cancer. of quarter colorectal appropriate in development for modest BMS used presenting treating that YERVOY. pretentiousness industry benefit antagonist who the some Outside of this Indeed failed stable of EGFR course by Slide enable and of specifically patient to of in we at population OPDIVO upon ASCO diagnosed rate XX
recently is PD-(L)X data months responses reported from left published no KETRUDA KEYNOTE-XXX median monotherapy with microsatellite stabilization. X.X a in the the the was with and On PFS positive
third On Phase data the opportunity colorectal Stivarga and of significant the combination stable trial. and of makes months to studied a is the cancer colorectal Again of median compared being point ASCO our Slide point microsatellite that a the PFS at is we market right cancer. X.X in the III GI main presented stable represents XX modest if is for of and at our clinical entinostat is currently we recently and in TECENTRIQ advocacy are anticipate reported. can very improved a microsatellite the of for view that XXX, in threshold from of conducting are these And rate and A X% in where from combination data demonstrate and response was Cotellic program Cotellic TECENTRIQ negative we're the line triple ovarian Both XXX the in ENCORE finally of ENCORE end of breast sensing next enrolling year. XX excitement our half summarize XXX Phase we II setting. clinical on the trials Again with and of first important from the in breadth this XXX these ENCORE and Slide cancer. trials are who pleased efficacy physicians year trials. cancer
up We this be of to extensively file half it the designed now turn monoclonal an broad AstraZeneca, slide. very SITC we start the with XXXX our withstands XX study last this year. potential IND covered the development multiple with the on receptor. about other on remain summarizes exciting study pleased XX XXXX Slide program that to indications We've SNDX-XXXX, cancer best program present ascending pre-clinical strategically oral antibody presentation the molecule. AACR our say more next class Infinity, program the And to both clinical summarizes CSF-X in for therapy of development have announce to collaboration ongoing. Ib prove that that's expand and and a we combination the ability and In April that pipeline. a been healthy finally Slide XXXX data an Menin-MLLr data Let in transactions at will coming generating that's To to dose with with at completed how patients were discussing our our a focused Phase as in which combination this now and we call and XX Phase in first and me to Menin-MLLr range year will an I acquire leukemias and is a of have volunteer we the of I clinical targeting later potentially on of shown anticipated slide November our quarter. XXXX the track is programs our January molecule
and and us clinical gives to closing of in the experience identify team agreement. extensive advantage relationships competitive us have team our allow that management development established Our assets a quality board
our significant this We that continue over to to for financial area And capability consider it spend update. Rick be effort this of to a in we and with I'll strength core turn the company.
